Form 4: Day One Biopharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Director Habib J. Dable acquired 32,335 stock options in Day One Biopharmaceuticals, Inc. on May 23, 2024.
Summary
- On May 23, 2024, Habib J. Dable, a director of Day One Biopharmaceuticals, Inc., acquired 32,335 stock options.
- The exercise price of these options is $13.87.
- The options vest monthly, starting June 23, 2024, and expire on May 22, 2034.
- Following the transaction, Dable directly owns 32,335 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in the biopharmaceutical industry to incentivize and align the interests of management with shareholders.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of the shareholders, incentivizing them to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of transaction: Director acquired stock options |
| 06/23/2024 | First vesting date for the stock options |
| 05/22/2034 | Expiration date of the stock options |
| 05/28/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.